Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Realistic timeline for results Patience is non-negotiable
Bioavailability from oral supplementation is notoriously low estimates range widely, but studies consistently show significant degradation occurs before meaningful absorption
Direct NAD+ IV Tolerability A small 2026 commercial-infusion study reported short-term tolerability data and variable exploratory metabolic outcomes, with more research needed beyond 30 days
Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production
/product/74/471494/1.jpg?2008)
US$ 24.98
US$ 22.91
US$ 27.30
US$ 20.75
US$ 20.22
